BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CLL Pharma and Leurquin-Mediolanum Announce Initiation of Phase 1b Clinical Trial of the Compound Syn1002 in Pain


7/2/2013 2:24:59 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CLL Pharma and Leurquin-Mediolanum announced today that enrollment has begun in a Phase 1b clinical trial of Syn1002 to demonstrate its proof of concept in validated human pain models.

This study follows the completion of the Phase 1 single dose-escalation study of Syn1002 which showed that the compound is very well tolerated in healthy volunteers. Syn1002 is a lead drug candidate, which has shown efficacy in various animal models of inflammatory and neuropathic pain and also in preclinical models of arthritis and Crohn’s disease.

Help employers find you! Check out all the jobs and post your resume.



 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES